To conclude, the profile analysis of FN-fibrin complexes and the determination of EDA-FN concentration, but not plasma FN in the plasma of patients, could be considered as a potential diagnostic biomarker helpful in diagnosis, management, and prophylaxis of patients with high risk of atherosclerosis and moreover may help to discriminate the group of patients with high risk of CAD from that with mild risk of CAD. This evidence concerns the gene FN1 and atherosclerosis.